Nenocorilant

PreclinicalSmall molecule

CCorcept Therapeutics

Nenocorilant is one of 31 small molecule programs targeting Neoplasms. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeoplasmsRecruiting

NeoplasmsPreclinical

Recruiting

Competition

Competitive Landscape

45 competitors in Neoplasms

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

1 2

Avastin

Roche

Phase 3

1 3

Taxol

Teva

Phase 3

1 4

Xtandi

Astellas

Phase 3

1 5

Alimta

SShawn Eagle

Phase 3

1 6

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

1 7

Fludara

Sanofi

Phase 2

3 8

Cyramza

Eli Lilly

Phase 2

1 9

Gemzar

Johnson & Johnson

Phase 2

1 10

Verzenio

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Neoplasms

NCT07276373

Clinical

Trials by Indication[1]

Neoplasms1 trial

A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies

Recruiting·CCorcept Therapeutics·Preclinical·NCT07276373·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nenocorilant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nenocorilant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nenocorilant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corcept Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCorcept Therapeutics

Nenocorilant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Neoplasms1 trial

References

Drug Info

Quick Facts

Related News